Perspective Therapeutics financials
$2.62+4.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81.0K | $76.0K | $43.0K | $209.0K | $290.0K | $342.0K | $234.0K | $369.0K | $526.0K | $325.0K | $337.0K | $276.0K |
| Gross profit | $81.0K | $76.0K | $43.0K | $209.0K | $290.0K | $342.0K | $234.0K | $369.0K | $526.0K | $325.0K | $337.0K | $276.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$29.3M | -$28.3M | -$39.8M | -$27.9M | -$24.0M | -$21.8M | -$45.0M | -$18.6M | -$14.3M | -$13.0M | -$11.7M | -$9.8M |
| Net income | -$26.8M | -$26.2M | -$37.5M | -$26.0M | -$21.5M | -$18.2M | -$40.2M | -$15.1M | -$11.7M | -$12.3M | -$24.7M | -$10.4M |
| Net margin | −33069.1% | −34459.2% | −87186.0% | −12425.4% | −7408.6% | −5314.9% | −17166.2% | −4098.1% | −2225.1% | −3779.7% | −7322.0% | −3752.2% |
| Diluted EPS | $-0.22 | $-0.25 | $-0.50 | $-0.35 | $-0.29 | $-0.25 | $-0.57 | $-0.21 | $-0.18 | $-0.25 | — | $-0.37 |
| EBITDA | -$28.1M | -$27.2M | -$38.8M | -$27.1M | -$23.3M | -$21.1M | -$20.2M | -$18.0M | -$13.7M | -$12.6M | -$11.7M | -$9.5M |
| Operating cash flow | -$20.6M | -$31.5M | -$24.7M | -$16.3M | -$20.0M | -$21.6M | -$26.6M | $3.4M | -$8.9M | $13.8M | -$9.0M | -$10.1M |
| Free cash flow | -$34.9M | -$38.3M | -$29.8M | -$18.3M | -$21.0M | -$26.2M | -$41.3M | -$26.4M | -$9.9M | $4.8M | -$9.1M | -$10.3M |
| Diluted shares | 120.7M | 103.6M | 74.4M | 74.3M | 74.2M | 72.4M | 70.9M | 70.6M | 66.6M | 49.5M | 78.6M | 28.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.5M | $54.0M | $30.6M | $26.8M | $28.8M | $44.4M |
| Short-term investments | $188.4M | $217.0M | $114.1M | $147.4M | $162.7M | $167.3M |
| Total debt | $1.6M | $1.6M | $1.6M | $1.6M | $1.7M | $1.7M |
| Total assets | $392.0M | $410.8M | $267.0M | $294.8M | $310.7M | $329.3M |
| Total liabilities | $68.2M | $63.3M | $59.9M | $52.6M | $45.0M | $44.7M |
| Shareholders' equity | $323.9M | $347.4M | $207.0M | $242.2M | $265.7M | $284.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology